


Synthesis of Vitamin D₃ Triene System by using Pd-Catalyzed Cyclization of Dienol Triflate

Hajime Yokoyama and Takashi Takahashi*


Department of Chemical Engineering, Tokyo Institute of Technology, Meguro, Tokyo 152, Japan

Abstract: The seco-B-ring triene system of 1 α ,2 β ,25-trihydroxy-vitamin D₃ is efficiently constructed by means of a palladium-catalyzed cyclization of the dienol triflate.
 © 1997, Elsevier Science Ltd. All rights reserved.


The increasing number of important potential clinical applications¹⁾ of 1 α , 25-dihydroxyvitamin D₃(Calcitriol) (**1**) and its analogues has stimulated significant effort toward the syntheses²⁾ of various calcitriol analogues having modified side chains and A-rings. Recent *in vivo* studies³⁾ on regulatory activities for calcium metabolism of 1 α ,25-dihydroxy-2 β -(3-hydroxypropoxy)vitamin D₃ (ED-71) (**2**) suggest it may be a promising drug for osteoporosis therapy.³⁾ One of the most crucial problem in the synthesis of vitamin D₃ is the stereoselective introduction of the seco-B-ring triene system. Construction of the triene system requires a short reaction time at a lower reaction temperature, higher temperature easily induces the "vitamin-previtamin equilibrium" *via* [1,7]-sigmatropic hydrogen shifts. Among the reported synthetic approaches to the triene system,⁴⁾ the phosphine oxide approach^{4a)} using **4** and **5** and the Pd-catalyzed cyclization approach^{4d)} using **6** and **7** are the most useful and versatile. In our synthetic plan for **2**⁵⁾ (Scheme 1), the triene system is constructed by Pd-catalyzed cyclization of the (*Z*)-dienol triflate **3**. In this communication, we describe the results of our initial efforts towards a total synthesis of **2**; the stereoselective synthesis of the model triene **18b** by using Pd-catalyzed cyclization of the (*Z*)-dienol triflate **12** (Scheme 3).



To establish the feasibility of our cyclization, the (*Z*)- and (*E*)-dienol triflate **12** and **13** were prepared in the following manner (Scheme 2). The aldehyde **8** was prepared from readily available 1,2;3,4;5,6-tri-*O*-isopropylidene-D-mannitol by our previous procedure.⁶ Cyanohydrin formation from aldehyde **8** (NaCN, NaHSO₃) and protection of the resulting alcohol (ethyl vinyl ether / H⁺) gave the protected cyanohydrin **9** in 80% overall yield. The alkylation⁷ of **9** with bromide **10** using potassium hexamethyldisilazide (KN(TMS)₂ / THF; 80% yield) and subsequent acid treatment of the alkylated product (*P*-TsOH / MeOH) followed by base treatment (2% NaOH / THF / H₂O) gave ketone **11** in 80% overall yield for the two steps. Regioselective enolate formation of **11** with KN(TMS)₂ at -78 °C in THF and quenching with *N*-phenyltrifluoromethanesulfonamide gave a 5:1 mixture of the (*Z*)- and (*E*)-dienol triflate **12** and **13** in 67% combined yield.⁸




Pd-catalyzed cyclization was performed as follows (Scheme 3). To a stirred solution of 10 mol% Pd(OAc)₂ and 20 mol% triphenylphosphine in DMF-triethylamine was added a solution of the (*Z*)-dienol triflate **12** in DMF. After stirring for 1 h at 20 °C, standard workup gave the (*Z*)-triene **18b** in 95% yield. The reaction



at 50 °C gave a 93:7 mixture of (*Z*)-**18b** and (*E*)-**19b**. At a higher temperature (110 °C), a 70:20:10 mixture of (*Z*)-**18b**, (*E*)-**19b** and **17b** was formed in 99% combined yield. Similarly, performing the reaction with the (*E*)-dienol triflate **13** at 20 °C gave the (*E*)-triene **19b** exclusively. At 110 °C, however, a mixture of (*E*)-**19b** and (*Z*)-**18b** was formed in a ratio of 90:10. The (*Z*)- and (*E*)-stereochemistry of the major trienes **18b** and **19b** was confirmed⁹⁾ by comparison of its ¹H-NMR spectrum with that of the trienes **18a** and **19a** reported by Trost's group.^{4d)} Thus the Pd-catalyzed cyclization using the dienol triflate proceeds with high stereoselectivity (>95%) at 20 °C and the [1,7]-sigmatropic hydrogen shift products, **17b** and **20b**, were not formed. The Pd-catalyzed alkylative enyne cyclization reported by Trost^{4d)} using **15** and **16**, required higher temperature (90–110 °C), and a provided 18: 50 mixture of the two major products **18b** and **17b** with trace amounts of two additional isomers **19b** and **20b**.

Based on Negishi's mechanism,¹⁰⁾ our speculation for the formation of the (*E*)-triene **19b** at 110 °C from the (*Z*)-dienol triflate **12** with inversion of the alkene configuration is as follows (Scheme 4). Cyclic carbopalladation ((*Z*)-**12** → (*Z*)-**14b** → (*Z*)-**21**), involving the addition of **12** to the Pd(0) species followed by addition of the resulting (*Z*)-alkenylpalladium **14b** to the terminal alkene with overall retention of the (*Z*)-dienyl configuration, gave the alkylpalladium intermediate (*Z*)-**21**. At this stage, two competitive processes are feasible; one is β-elimination of the palladium species giving the (*Z*)-triene **18b** and the other is cyclopropanation of alkylpalladium (*Z*)-**21** affording the cyclopropylcarbinyl palladium **22**. The reversible "cyclopropylcarbinyl to homoallyl palladium" rearrangement of **22** to the alkylpalladium intermediates (*Z*)-**21** and (*E*)-**23**, followed by β-elimination of the palladium species gave the trienes (*Z*)-**18b** and (*E*)-**19b**, respectively. At 20 °C, however, the β-elimination process is faster than the cyclopropanation. Consequently, the reaction of (*Z*)-**12** at 20 °C gave exclusively the (*Z*)-triene **18b**, although the reaction carried out at 110 °C afforded a mixture of (*Z*)-**18b** and (*E*)-**19b**. Similarly, the formation of the (*Z*)-triene **18b** from the (*E*)-dienol triflate **13** at 110 °C and the exclusive formation of (*E*)-**19b** from (*E*)-**13** at 20 °C can be rationalized.



Thus the palladium-catalyzed cyclization using the dienol triflate is useful to construct the thermally labile triene system of vitamin D₃. We also found that the homoallyl palladium intermediates, like **21** and **23**,

undergo the cyclopropanation at higher temperature (>80 °C), while at lower temperature (<50 °C) the β -elimination of the homoallyl palladium species becomes dominant. Further studies on the total synthesis of ED-71 using Pd-catalyzed cyclization of dienol triflates are underway in our laboratory.

References and Notes

- 1) Norman, A.W.; Bouillon, R.; Thomasset, M., Eds.; *Vitamin D: Gene Regulation, Structure Function Analysis and Clinical Application*; Walter de Gruyter and Co.: Berlin; 1991.
- 2) Review; a) Zhu, G-D.; Okamura, W.H. *Chem. Rev.* **1995**, *95*, 1877-1952. b) Dai, H.; Posner, G. H. *Synthesis*, **1994**, 1383-1398. c) Kametani, T.; Furuyama, H. *Med. Res. Rev.* **1987**, *7*, 147-171. d) Lythgoe, B. *Chem. Soc. Rev.* **1980**, *9*, 449-475. e) Georghiou, P. E. *Chem. Soc. Rev.* **1977**, *6*, 83-107.
- 3) Okano, T.; Tsugawa, N.; Masuda, S.; Takeuchi, A.; Kobayashi, T.; Takita, Y.; Nishii, Y. *Biochem. Biophys. Res. Commun.* **1989**, *163*, 1444-1449.
- 4) a) Lythgoe-Roche phosphine oxide approach; Baggolini, E. G.; Iacobelli, J. A.; Hennessy, B. M.; Uskokovic, M. R. *J. Am. Chem. Soc.* **1982**, *104*, 2945-2948. :Kocienski, P. J.; Lythgoe, B. J. *Chem. Soc. Perkin Trans. 1* **1980**, 1400-1404., b) Lythgoe-Mourino dienyne approach; Castedo, L.; Mascarenas, J. L.; Mourino, A.; Sarandeses, L. A. *Tetrahedron Lett.* **1988**, *29*, 1203-1206. :Harrison, R. G.; Lythgoe, B.; Wright, P. W. *Tetrahedron Lett.* **1973**, 3649-3652., c) Okamura vinylallene approach; Okamura, W. H.; Aurrecochea, J. M.; Gibbs, R. A.; Norman, A. W. *J. Org. Chem.* **1989**, *54*, 4072-4083., d) Trost seco-A-ring enyne approach; Trost, B. M.; Dumas, J.; Villa, M. *J. Am. Chem. Soc.* **1992**, *114*, 9836-9845.
- 5) Takahashi, T.; Nakazawa, M. *Synlett* **1993**, 37-39.
- 6) Takahashi, T.; Nakazawa, M.; Sakamoto, Y.; Houk, K. N. *Tetrahedron Lett.* **1993**, *34*, 4075-4078.
- 7) Stork, G.; Depezay, J. C.; d'Angelo, J. *Tetrahedron Lett.* **1975**, 389-392.
- 8) **12b** ¹H-NMR(CDCl₃, 270 MHz) δ =6.24 (1H, d, J = 11.2 Hz), 5.96 (1H, d, J = 11.2 Hz), 5.79-5.92 (1H, m), 5.43 (1H, d, J = 17.2 Hz), 5.30 (1H, d, J = 10.2 Hz), 4.75 (1H, d, J = 6.9 Hz), 4.61 (1H, d, J = 6.9 Hz), 4.35 (1H, t, J = 7.6 Hz), 3.98-4.03 (1H, m), 3.83-3.87 (1H, m), 3.33 (3H, brs), 2.50-2.80 (2H, m), 2.10-2.40 (4H, m), 1.40-1.80 (12H, m). IR (neat) 3026, 2890, 1629, 1564 cm⁻¹.
13b ¹H-NMR(CDCl₃, 270 MHz) δ =6.47 (1H, d, J = 11.6 Hz), 5.70-6.00 (2H, m), 5.43 (1H, d, J = 16.2 Hz), 5.29 (1H, d, J = 10.2 Hz), 4.60-4.80 (2H, m), 4.30-4.40 (1H, m), 3.90-4.10 (1H, m), 3.80-3.90 (1H, m), 3.35 (3H, brs), 2.90 (1H, dd, J = 7.9 Hz), 2.63 (1H, dd, J = 3.96, 15.8 Hz), 2.00-2.40 (4H, m), 1.30-1.70 (12H, m). IR (neat) 3024, 2854, 1620, 1552 cm⁻¹.
- 9) **18b** ¹H-NMR(CDCl₃, 270 MHz) δ =6.32 (1H, d, J = 11.0 Hz), 6.20 (1H, d, J = 11.0 Hz), 5.31 (1H, t, J = 1.9 Hz), 4.98 (1H, t, J = 1.9 Hz), 4.82 (1H, d, J = 6.7 Hz), 4.70 (1H, d, J = 6.7 Hz), 4.40 (1H, dt, J = 9.9, 1.9 Hz), 4.30-4.33 (1H, m), 3.58 (1H, dd, J = 2.3, 10 Hz), 3.39 (3H, br s), 2.50-2.60 (2H, m), 2.10-2.40 (4H, m), 1.40-1.70 (12H, m). IR (neat) 3032, 2888, 1643 cm⁻¹.
19b ¹H-NMR(CDCl₃, 270 MHz) δ =6.62 (1H, dd, J = 11.7, 2.5 Hz), 5.96 (1H, d, J = 11.7 Hz), 5.07 (1H, t, J = 1.7 Hz), 4.94 (1H, t, J = 1.7 Hz), 4.85 (1H, d, J = 6.9 Hz), 4.72 (1H, d, J = 6.9 Hz), 4.51-4.56 (1H, m), 4.35-4.39 (1H, m), 3.55-3.60 (1H, m), 3.38 (3H, br s), 3.08-3.16 (1H, m), 2.10-2.40 (5H, m), 1.40-1.80 (12H, m). IR (neat) 3024, 2854, 1630 cm⁻¹.
- 10) Owczarczyk, Z.; Lamaty, F.; Vawter, E. J.; Negishi, E. *J. Am. Chem. Soc.* **1992**, *114*, 10091-10092.